




(72) DARBOURET, ANNE, FR

(72) BRUNEL, FLORENCE, FR

(72) RONCO, JORGE, FR

(71) AVENTIS PASTEUR, FR

(51) Int.Cl.⁷ A61K 39/39, A61K 39/29

(30) 1998/07/03 (98/08700) FR

(54) **UTILISATION D'UN COMPOSE AMPHIPATHIQUE POUR
ADJUVER UN VACCIN SOUS-UNITAIRE**

(54) **USE OF AN AMPHIPATHIC COMPOUND FOR PROVIDING AN
ADJUVANT TO A SUBUNIT VACCINE**

(57) L'invention a pour objet l'utilisation d'un composé amphipathique pour la préparation d'une composition vaccinale comprenant au moins un antigène sous-unitaire destinée à être administrée à des populations-cibles comprenant des individus "Non-Répondeurs" audit antigène. Un composé amphipathique particulier est le DC-chol.

(57) The invention concerns an amphipathic compound for preparing a vaccine composition comprising at least a subunit antigen to be administered to target populations comprising non-responders to said antigen. DC-chol is a particular amphipathic compound.

PCTORGANISATION MONDIALE DE LA PROPRIÉTÉ INTELLECTUELLE
Bureau international

DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITE DE COOPERATION EN MATIÈRE DE BREVETS (PCT)

(51) Classification internationale des brevets ⁶ : A61K	A2	(11) Numéro de publication internationale: WO 00/01345 (43) Date de publication internationale: 13 janvier 2000 (13.01.00)
(21) Numéro de la demande internationale: PCT/FR99/01604 (22) Date de dépôt international: 2 juillet 1999 (02.07.99) (30) Données relatives à la priorité: 98/08700 3 juillet 1998 (03.07.98) FR (71) Déposant (pour tous les Etats désignés sauf US): PASTEUR MERIEUX SERUMS & VACCINS [FR/FR]; 58, avenue Leclerc, F-69007 Lyon (FR). (72) Inventeurs; et (75) Inventeurs/Déposants (US seulement): DARBOURET, Anne [FR/FR]; La Revanche, F-69440 Saint Maurice sur Dargoire (FR). BRUNEL, Florence [FR/FR]; 41, rue Rey Loras, Résidence Ombreval, Allée AI, F-69250 Neuville sur Saône (FR). RONCO, Jorge [AR/FR]; 45, rue de la Cadière, F-69350 La Mulatière (FR). (74) Mandataire: KERNEIS, Danièle; Pasteur Mérieux Sérums et Vaccins, Direction de la Propriété Industrielle, 58, avenue Leclerc, F-69007 Lyon (FR).		(81) Etats désignés: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, brevet ARIPO (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), brevet eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Publiée <i>Sans rapport de recherche internationale, sera republiée dès réception de ce rapport.</i>
(54) Title: USE OF AN AMPHIPATHIC COMPOUND FOR PROVIDING AN ADJUVANT TO A SUBUNIT VACCINE (54) Titre: UTILISATION D'UN COMPOSE AMPHIPATHIQUE POUR ADJUGER UN VACCIN SOUS-UNITAIRE (57) Abstract The invention concerns an amphipathic compound for preparing a vaccine composition comprising at least a subunit antigen to be administered to target populations comprising non-responders to said antigen. DC-chol is a particular amphiphatic compound. (57) Abrégé L'invention a pour objet l'utilisation d'un composé amphipathique pour la préparation d'une composition vaccinale comprenant au moins un antigène sous-unitaire destinée à être administrée à des populations-cibles comprenant des individus "Non-Répondeurs" audit antigène. Un composé amphipathique particulier est le DC-chol.		

WO 00/01345

PCT/FR99/01604

USE OF AN AMPHIPATHIC COMPOUND
FOR PROVIDING AN ADJUVANT TO A SUBUNIT VACCINE

5 The invention relates to the field of vaccine
adjuvants. In particular, the invention relates to the
use of an amphipathic compound for the manufacture of a
vaccine composition intended for nonresponding
subjects.

10 It is known that, when a population of
individuals is vaccinated against a disease, a number
of them do not "respond" to the vaccination, that is to
say that their immune system does not appear to react
to the antigen administered. This problem is
15 substantial to a greater or lesser degree depending on
the diseases and the populations involved, but vaccine
manufacturers are still trying to reduce, for each of
the vaccines which they make available to doctors, the
number of subjects likely to be "nonresponders". This
20 problem is considered particularly for vaccines
comprising purified antigens such as subunit vaccines
produced by genetic engineering and in particular the
hepatitis vaccine; however, while a number of
amphipathic compounds, and in particular 3- β -[N-(N',N'-
25 dimethylaminoethane)carbamoyl]cholesterol, commonly
called DC-chol, are known which make it possible to
increase the immune response in subjects who are
already "responders", and are therefore considered to
be good vaccine adjuvants, it is more difficult to find
30 means of overcoming the problem of nonresponders, all
the more so since all the reasons why an individual is
a nonresponder have not yet been clearly identified.
The research studies carried out in this field have
shown that it was not possible to extrapolate the
35 results obtained with adjuvants capable of increasing
the immune response in "responding" subjects to the
"nonresponding" subjects, given that some good
adjuvants in responding subjects are found to have no
effect in nonresponding subjects.

- 2 -

The aim of the invention is therefore to provide an improved vaccine as regards the level of seroconversion which it makes possible to obtain. For that, the invention proposes the use of an amphipathic compound for the preparation of a vaccine composition comprising at least one subunit antigen intended to be administered to target populations comprising individuals who are "nonresponders" to said antigen.

According to the invention, the amphipathic compounds are cholesterol derivatives attached to a quaternary ammonium or to a protonable amine by a carbamoyl bond. These compounds, such as DC-chol, can exist in the basic form, in the salt form or alternatively, and this is the most frequent case, in both of the two forms in equilibrium in a mixture, the shifting of the equilibrium toward either form depending on the composition of the mixture and in particular on its pH. One of the particularly advantageous amphipathic compounds for the purposes of the invention is DC-chol which may be obtained from cholesteryl chloroformate and from N,N-dimethylethylenediamine, according to the method described in patent US 5283185 or, preferably, according to the method described in Example 8 of patent application WO 96/40067. The 2 forms of DC-chol generally in equilibrium are illustrated in Figure 1. It is also possible to use a product obtained by reacting cholesteryl chloroformate and N,N,N-trimethylethylenediamine.

The amphipathic compounds may exist in the form of a dispersion in an aqueous or oily medium.

The vaccine composition which needs to be modified so as to reduce the number of individuals who are nonresponders thereto is a composition comprising at least one highly purified subunit antigen. Indeed, such antigens are in general less immunogenic than less purified preparations obtained from whole microorganisms and may therefore lead to a higher proportion of nonresponders. In particular, according

- 3 -

to the invention, the number of nonresponders to the hepatitis B antigen is reduced. This may be any hepatitis B antigen, and in particular an antigen containing the S and pre-S₂ regions, such as the
5 antigen described in patent EP 0 273 811.

To assess the efficacy of the subject of the invention, animal models are used. The results obtained with the compounds according to the invention and those obtained with conventional prior art adjuvants are thus
10 compared in parallel on a group of nonsyngenic OF 1 mice which, like the human population, is composed of both responding subjects and nonresponding subjects. Comparison of the number of subjects to have undergone seroconversion in each of the groups makes it possible
15 to assess the benefit of the subject of the invention.

Another test may be performed on mice belonging to a strain described as being a nonresponder to the antigen considered, such as the B10.MH^{2f} mice for the hepatitis B antigen. Comparison of the results obtained
20 in each of the groups makes it possible to assess the efficacy of the subject of the invention.

The vaccine composition according to the invention may be provided in liquid form or in freeze-dried form.

25 The vaccine composition according to the invention may be a monovalent composition (that is to say which is intended to protect against only one disease) or a multivalent composition (which protects against several diseases).

30 It may comprise, in addition to the adjuvant according to the invention, one or more other adjuvants conventionally intended to increase the response of the immune system, whether this is a humoral-type or a cellular-type response, or a combination of both types.

35 Conventionally, the vaccine composition according to the invention may comprise, in addition, all the ingredients usually present in vaccines: stabilizer, preservative, cryoprotectant and the like.

- 4 -

This composition may be provided in liquid form or in freeze-dried form.

The following examples illustrate an embodiment of the invention.

5 Figure 1 represents the reaction for producing DC-chol. Figures 2 and 3 illustrate the results obtained in Example 2.

10 Example 1: Preparation of the compositions for immunization

 A suspension of hepatitis B antigen is prepared according to the method described in patent EP 0 273 811, with the exception of the addition of aluminum hydroxide. This is therefore a suspension
15 containing 4 mg/l of antigen in 1 mM phosphate buffer at pH 6.8. This suspension is called Suspension A.

 DC-chol powder obtained according to the mode of preparation described in Example 8 of patent application WO 96/40067 is available. This powder is
20 suspended in 20 mM Tris/HCl buffer containing 150 mM NaCl at pH 6.8, under nitrogen at 4°C while the stirring is maintained for 48 h. A suspension containing 2 g/l of DC-chol is thus obtained.

 By mixing these 2 suspensions volume for
25 volume, a vaccine composition according to the invention is obtained which is divided into 0.5 ml doses, each comprising 1 µg of antigen against hepatitis B and 0.5 mg of DC-chol.

 A new immunizing composition comprising, this
30 time, 1 µg of antigen and 1 mg of aluminum hydroxide per 0.5 ml dose is prepared by adding aluminum hydroxide (Alhydrogel® provided by the company SUPERFOS BIOSECTOR) to suspension A.

 A new composition for immunization is prepared
35 from suspension A to which a prior art adjuvant C is added in order to obtain per 0.5 ml dose a quantity of antigen of 1 µg and a quantity of adjuvant of 0.5 mg. The nature and the dose of the prior art adjuvant were selected during comparative immunization trials against

- 5 -

hepatitis B in BALB/C mice, by the subcutaneous route. The adjuvant selected is that which, during these trials, showed a high capacity to increase the humoral response of the antigen considered, the results
5 obtained with this adjuvant being considerably superior to those obtained with aluminum hydroxide or with DC-chol.

Example 2: Immunization of OF1 mice

10 There are 4 groups of 10 nonsyngenic OF1 female mice, 6 to 8 weeks old, which represent a heterogeneous population reflecting the variability in the human population.

15 Each group of mice is immunized with a different vaccine composition:

- a 1st group is immunized with 0.5 ml doses of the suspension A mentioned in Example 1, and therefore containing only the hepatitis B antigen
- 20 ▪ a second group is immunized with 0.5 ml doses each comprising the hepatitis B antigen and aluminum hydroxide
- a third group is immunized with 0.5 ml doses each comprising the hepatitis B antigen and a prior art adjuvant
- 25 ▪ a fourth group is immunized with 0.5 ml doses of the vaccine composition according to the invention.

The mice are immunized by the subcutaneous route, one to two hours after the preparation of the immunizing compositions.

30 Three weeks after the first immunization, blood is collected for assaying, and a second injection is carried out under the same conditions as the first. A second blood sample is collected three weeks after the second injection. All the blood samples are coagulated
35 and centrifuged; the serum harvested is stored at -20°C up to titration which is carried out by an ELISA technique.

The results obtained for each of the groups of mice are illustrated in Figure 2 which indicates, in

- 6 -

arbitrary ELISA units, the geometric mean antibody titers (GMT) obtained with each of the compositions tested after the 1st injection, and in Figure 3 which indicates the GMT means obtained after the booster
5 injection.

It will thus be noted that, from the first injection, there is no nonresponding subject in the group of mice which received the vaccine composition according to the invention, whereas the use of the
10 prior art adjuvant, which is nevertheless capable of substantially increasing the immune response in mice which are already "responders", does not make it possible, even after the booster injection, to make all the subjects "responders".

15

Example 3: Immunization of B10.MH^{2f} mice

The 4 preparations for immunization described in Example 2 are available which are administered, this time, to 4 groups of 8 B10.M mice which are mice
20 described as being "nonresponders" to the hepatitis B antigen.

The immunization protocol is the same as that in Example 2.

The results obtained are indicated in Table 1
25 below; this includes the number of mice which have undergone seroconversion, after the booster injection, in each of the groups tested.

For this test, it is considered that there is seroconversion when the levels of antibodies induced
30 are detectable during ELISA assay.

Table 1

MOUSE GROUP	NUMBER OF "RESPONDERS"
Hbs antigen alone	1/8
Ag + Al hydroxide	0/8
Ag + prior art adjuvant	0/8
Ag + DC-chol	5/8

- 7 -

The results obtained show the efficacy of the
subject of the invention which makes it possible to
increase the level of seroconversion and therefore to
reduce the number of "nonresponding" subjects during
5 immunization against a highly purified antigen.

WO 00/01345

- 8 -

PCT/FR99/01604

CLAIMS

1. The use of an amphipathic compound for the preparation of a vaccine composition comprising at least one subunit antigen intended to be administered to target populations comprising individuals who are "nonresponders" to said antigen.
2. The use as claimed in claim 1, wherein said antigen is an antigen for vaccinating against hepatitis B.
3. The use as claimed in either of the preceding claims, wherein said amphipathic compound is DC-chol.
4. The use as claimed in one of the preceding claims, wherein the vaccine composition is a multivalent composition.
5. The use as claimed in one of the preceding claims, wherein the amphipathic compound is present in the form of a dispersion in an aqueous or oily medium.
6. The use as claimed in one of the preceding claims, wherein the amphipathic compound is present in a freeze-dried formulation.
7. The use as claimed in one of the preceding claims, which comprises, in addition, at least one other vaccine adjuvant.

1/2




FIG 1

FIG 2

FIG 3